Investigational drug · Phase 3
Furmonertinib
Not approved by FDA. In 8 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-Small Cell Lung Cancer, NSCLC, NSCLC Patients With Brain Metastasis.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
8
8 still active
All registered trials
79
Any phase or sponsor naming "Furmonertinib"
First trial start
2021
Jun 7, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Furmonertinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-Small Cell Lung Cancer
- NSCLC
- NSCLC Patients With Brain Metastasis
- Advanced Lung Cancer
- Metastatic Non-Small Cell Lung Cancer
- Advanced Non-Small Cell Lung Cancer
- EGFR Exon 20 Mutations
- Non-small Cell Lung Carcinoma
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Furmonertinib" as an intervention, largest first.
- Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationRecruiting
Hunan Province Tumor HospitalAcademic, hospital or other
NCT04322890 · 6,000 participants (planned) · Start Apr 16, 2020 · Primary completion Dec 24, 2026
Drug: Osimertinib; Alectinib 150 MG and 3 more · For: Non Small Cell Lung Cancer; EGFR Gene Mutation; ALK Gene Mutation and 2 more
Sites: Changsha, China
Fudan UniversityAcademic, hospital or other
NCT06613633 · 4,000 participants · Start Sep 1, 2018 · Primary completion Aug 1, 2024
Drug: third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib) · For: Third-generation TKI; NSCLC (Advanced Non-small Cell Lung Cancer)
Sites: Wuhan, China; Shanghai, China · 3 sites in all
Hunan Province Tumor HospitalAcademic, hospital or other
NCT04324164 · 800 participants (planned) · Start Mar 24, 2020 · Primary completion Dec 24, 2025
Drug: Third-generation EGFR-TKI; EGFR-TKI · For: Non-small Cell Lung Cancer
Sites: Changsha, China
Fudan UniversityAcademic, hospital or other
NCT06604689 · 800 participants (planned) · Start Sep 30, 2024 · Primary completion Apr 1, 2025
Drug: third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib) · For: NSCLC (Advanced Non-small Cell Lung Cancer); Brain Metastasases
Sites: Shanghai, China
- Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC:Prospective StudyPivotal-lookingStatus unknown
Tian XieAcademic, hospital or other
NCT04401059 · 744 participants (planned) · Start Nov 9, 2020 · Primary completion Sep 30, 2025
Drug: Elemene plus first or third generation EGFR-TKIs; First or third generation EGFR-TKIs · For: Carcinoma; Non-Small-Cell Lung Cancer; Adenocarcinoma
Sites: Nantong, China; Panjin, China; Shanghai, China · 7 sites in all
ArriVent BioPharma, Inc.Industry
NCT07185997 · 480 participants (planned) · Start Dec 17, 2025 · Primary completion Feb 2029
Drug: Firmonertinib; EGFR-TKI inhibitor based on investigator's choice · For: Non-Small-Cell Lung Cancer; Metastatic Non-Small-Cell Lung Cancer; Advanced Non-Small-Cell Lung Cancer and 3 more
Sites: Fullerton, California; Los Angeles, California; Orange, California · 141 sites in all
MediLink Therapeutics (Suzhou) Co., Ltd.Industry
NCT07169994 · 414 participants (planned) · Start Sep 2, 2025 · Primary completion Sep 1, 2026
Drug: YL202 for injection; Toripalimab injection; YL202 for injection; Furmonertinib Mesilate Tablets · For: Advanced Solid Tumors; Breast Cancer; Non Small Cell Lung Cancer
Sites: Hefei, China; Fuzhou, China; Guangzhou, China · 20 sites in all
- Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)Pivotal-lookingActive, not recruiting
ArriVent BioPharma, Inc.Industry
NCT05607550 · 398 participants · Start Jun 1, 2023 · Primary completion Oct 6, 2026
Drug: furmonertinib 240 mg oral, daily; furmonertinib 160 mg oral, daily and 1 more · For: Metastatic Non-Small Cell Lung Cancer; Advanced Non-Small Cell Lung Cancer; EGFR Exon 20 Mutations
Sites: Daphne, Alabama; Yuma, Arizona; Fayetteville, Arkansas · 208 sites in all
Allist Pharmaceuticals, Inc.Industry
NCT06970639 · 380 participants (planned) · Start Sep 26, 2024 · Primary completion Mar 2029
Drug: Furmonertinib Mesilate Tablets; Carboplatin Injection and 3 more · For: NSCLC Patients With Brain Metastasis
Sites: Guangdong, China
- Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAG)Pivotal-lookingActive, not recruiting
Allist Pharmaceuticals, Inc.Industry
NCT03787992 · 358 participants · Start May 30, 2019 · Primary completion Sep 15, 2021
Drug: Alflutinib Mesylate (AST2818) 80mg//40 mg+ placebo; Placebo Gefitinib 250 mg and 2 more · For: Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Targeted LC-MS/MS profiling highlights altered cerebrospinal fluid glutathione in cancer patients with CNS metastases.
Zhao X, Cui J, Wang Y, et al. · J Pharm Biomed Anal 2026
- Reassessing the Incidence and Risk Factors of Radiation Pneumonitis in Treatment-Naive EGFR-Mutant NSCLC With Concurrent Third-Generation EGFR-TKI and Thoracic Radiotherapy.
Zheng S, Jia W, Jing X, et al. · Int J Cancer 2026
- Long-Term Recurrence-Free Survival After Surgery and Adjuvant Furmonertinib in a Patient With EGFR-Mutated Pulmonary Sarcomatoid Carcinoma: A Case Report.
Nong M, Tan X · Cancer Rep (Hoboken) 2026
- Furmonertinib activity in NSCLC Harbouring EGFR L858R and ERBB2 S310F co-mutations: a case report with literature review.
Liu S, Cao R, Li H, et al. · J Chemother 2026
- Perioperative treatment for resectable non-small cell lung cancer harboring EGFR exon 20 insertion mutations: a narrative review from advanced-stage evidence to whole-course precision management.
Li Z, Han Y, Zhong W, et al. · Transl Lung Cancer Res 2026
- Case Report: Cholestatic liver injury during atezolizumab therapy in EGFR-mutant combined small cell lung cancer with possible underlying primary biliary cholangitis.
Zhu Y, Xiong J, Tan C, et al. · Front Oncol 2026
Also in development for Non-Small Cell Lung Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.